SMZ1.SG
Sino Biopharmaceutical Limited
StuttgartEUREQUITY
DELAYED
Last price
0.60
▼ 0.01 (0.84%)
MARKET · —
Price
Chart style
Interval
Intraday intervals only cover recent history. The site picks the finest interval the range allows.
Overlays
Session levels
Lower pane
Overlay another symbol
Both series are rebased to 0% at the left edge, so the lines show relative performance rather than price.
Tool
1D
—
H —
L —
Range —
Vol —
vs
Drag pan · Pinch zoom · Hold crosshair · pick a tool then drag to draw
Open
0.59
Prev close
0.61
Day high
0.60
Day low
0.59
Volume
850
Market cap
—
P/E (TTM)
—
52W range
0.36 – 0.99
Day trading desk
Gap from prior close
—
—
VWAP
0.60
+0.05% from price
Relative volume
—
—
Session range
2.20%
0.59 – 0.60
Position in range
82%
Near session high
ATR (14D)
—
Daily true range
Prior day high
—
PDH
Prior day low
—
PDL
Bid / ask spread
—
Quote not published
Session volume
850
Shares traded
VWAP and the session figures are computed from the delayed intraday series on this page, so they lag the live tape and will not match a broker's real-time VWAP exactly. Turn on Prior day H/L/C, Opening range and Volume profile in the chart's Studies menu to see these levels drawn on price.
Free account
3 more panels on SMZ1.SG open with an account.
Options chains and analytics, valuation ratios, insider filings, analyst targets and ownership. No card, no trial, nothing to cancel.
Fundamentals
Market cap—
Enterprise value—
Revenue (TTM)—
Gross profit—
EBITDA—
Net income—
EPS (TTM)—
Free cash flow—
Total cash—
Total debt—
Book value / share—
Shares outstanding—
Float—
Short % of float—
Dividend yield—
Beta (5Y)—
Valuation & profitability ratios
Trailing P/E—
Forward P/E—
PEG ratio—
Price / sales—
Price / book—
EV / revenue—
EV / EBITDA—
Gross margin—
Operating margin—
Profit margin—
Return on equity—
Return on assets—
Debt / equity—
Current ratio—
Fourteen ratios including P/E, PEG, EV/EBITDA, margins and return on equity.
Financial statements
| Line item | 2025 | 2024 | 2023 | 2022 | YoY |
|---|---|---|---|---|---|
| Total revenue | $31.83B | $28.87B | $26.20B | $26.03B | +10.3% |
| Operating revenue | $31.83B | $28.87B | $26.20B | $26.03B | +10.3% |
| Cost of revenue | $5.71B | $5.34B | $4.99B | $4.49B | +7.0% |
| Gross profit | $26.13B | $23.53B | $21.21B | $21.54B | +11.0% |
| Research & development | $5.87B | $5.09B | $4.40B | $4.16B | +15.3% |
| Selling, general & admin | $13.14B | $12.16B | $11.07B | $11.71B | +8.0% |
| Total operating expense | $19.23B | $17.20B | $15.12B | $16.06B | +11.8% |
| Operating income | $6.90B | $6.33B | $6.09B | $5.48B | +8.9% |
| Net interest income | $355.28M | $204.45M | -$116.90M | -$233.59M | +73.8% |
| Pre-tax income | $6.94B | $5.28B | $5.41B | $5.21B | +31.6% |
| Tax provision | $1.63B | $492.92M | $797.27M | $696.72M | +230.5% |
| Net income | $2.34B | $3.50B | $2.33B | $2.54B | -33.0% |
| Net income to common | $2.34B | $3.50B | $2.54B | $2.31B | -33.0% |
| EBIT | $7.22B | $5.57B | $5.91B | $5.64B | +29.6% |
| EBITDA | $8.43B | $6.89B | $6.98B | $6.69B | +22.3% |
| Line item | 2025 | 2024 | 2023 | 2022 | YoY |
|---|---|---|---|---|---|
| Cash & equivalents | $12.18B | $9.57B | $9.45B | $12.07B | +27.3% |
| Cash & short-term investments | $22.96B | $14.82B | $14.12B | $16.92B | +55.0% |
| Accounts receivable | $5.70B | $4.31B | $3.80B | $3.72B | +32.2% |
| Inventory | $2.26B | $2.37B | $1.99B | $2.33B | -4.9% |
| Total current assets | $34.47B | $24.69B | $23.81B | $25.93B | +39.6% |
| Property, plant & equipment | $10.23B | $10.29B | $9.91B | $9.25B | -0.5% |
| Goodwill & intangibles | $7.05B | $3.06B | $2.91B | $1.91B | +130.4% |
| Total assets | $76.01B | $65.41B | $63.60B | $64.06B | +16.2% |
| Total current liabilities | $25.20B | $19.56B | $22.61B | $20.15B | +28.9% |
| Current debt | $8.40B | $7.60B | $11.14B | $9.66B | +10.4% |
| Long-term debt | $7.58B | $2.00B | $1.07B | $3.93B | +279.8% |
| Total debt | $16.07B | $9.71B | $12.58B | $13.98B | +65.5% |
| Total liabilities | $33.92B | $22.63B | $25.43B | $26.12B | +49.9% |
| Retained earnings | $24.95B | $25.28B | $23.65B | $23.07B | -1.3% |
| Shareholder equity | $30.67B | $31.96B | $30.47B | $29.75B | -4.0% |
| Working capital | $9.27B | $5.13B | $1.20B | $5.78B | +80.7% |
| Net tangible assets | $23.62B | $28.90B | $27.57B | $27.83B | -18.3% |
| Shares issued | 18.76B | 18.79B | 18.80B | 18.81B | -0.2% |
| Line item | 2025 | 2024 | 2023 | 2022 | YoY |
|---|---|---|---|---|---|
| Depreciation & amortisation | $1.21B | $1.32B | $1.07B | $1.05B | -8.3% |
| Stock-based compensation | $115.97M | $53.72M | $18.12M | $29.72M | +115.9% |
| Change in working capital | $2.62B | $99.84M | -$430.51M | -$195.59M | +2,528.7% |
| Operating cash flow | $9.29B | $6.62B | $6.07B | $6.27B | +40.5% |
| Capital expenditure | -$1.70B | -$1.39B | -$1.70B | -$1.71B | -22.1% |
| Investing cash flow | -$12.41B | -$1.71B | -$756.98M | -$4.07B | -626.3% |
| Share buybacks | -$110.00M | -$1.25B | -$396.39M | -$867.61M | +91.2% |
| Dividends paid | -$1.50B | -$1.85B | -$632.67M | -$1.27B | +18.6% |
| Financing cash flow | $4.16B | -$6.32B | -$6.55B | -$3.19B | +165.8% |
| Free cash flow | $7.59B | $5.22B | $4.36B | $4.56B | +45.4% |
| End cash position | $7.38B | $6.23B | $7.51B | $8.65B | +18.5% |
No filings published for this symbol yet.
Newly listed companies often have nothing on file until their first annual report.
Newly listed companies often have nothing on file until their first annual report.
| Line item | 2025-12-31 | 2025-06-30 | 2024-12-31 | YoY |
|---|---|---|---|---|
| Cash & equivalents | $12.18B | $11.10B | $9.57B | +9.7% |
| Cash & short-term investments | $22.96B | $19.82B | $14.82B | +15.8% |
| Accounts receivable | $5.70B | $8.15B | $4.31B | -30.1% |
| Inventory | $2.26B | $2.10B | $2.37B | +7.3% |
| Total current assets | $34.47B | $33.82B | $24.69B | +1.9% |
| Property, plant & equipment | $10.23B | $10.05B | $10.29B | +1.8% |
| Goodwill & intangibles | $7.05B | $3.12B | $3.06B | +126.1% |
| Total assets | $76.01B | $74.89B | $65.41B | +1.5% |
| Total current liabilities | $25.20B | $24.85B | $19.56B | +1.4% |
| Current debt | $8.40B | $8.85B | $7.60B | -5.2% |
| Long-term debt | $7.58B | $3.00B | $2.00B | +152.8% |
| Total debt | $16.07B | $11.96B | $9.71B | +34.4% |
| Total liabilities | $33.92B | $29.12B | $22.63B | +16.5% |
| Retained earnings | $24.95B | $28.02B | $25.28B | -10.9% |
| Shareholder equity | $30.67B | $33.37B | $31.96B | -8.1% |
| Working capital | $9.27B | $8.97B | $5.13B | +3.3% |
| Net tangible assets | $23.62B | $30.25B | $28.90B | -21.9% |
| Shares issued | 18.76B | 18.76B | 18.79B | 0.0% |
No filings published for this symbol yet.
Newly listed companies often have nothing on file until their first annual report.
Newly listed companies often have nothing on file until their first annual report.
Analyst targets & ownership
Mean target—
High target—
Low target—
Implied upside—
Analyst count—
Consensus—
Strong buy / Buy— / —
Hold—
Sell / Strong sell— / —
Held by insiders—
Held by institutions—
Institutions holding—
Price targets, consensus spread, insider and institutional ownership.
Moving averages & technicals
SMA 10
—
—
SMA 20
—
—
SMA 50
—
—
SMA 100
—
—
SMA 200
—
—
EMA 12
—
—
EMA 26
—
—
EMA 50
—
—
RSI (14)
—
—
MACD (12,26,9)
—
Hist —
ATR (14)
—
—
Realised vol 30D
—
Annualised
Bollinger upper
—
20, 2σ
Bollinger lower
—
20, 2σ
50 / 200 cross
—
—
Trend bias
—
—
Options chain
Calls
| Strike | Last | Bid | Ask | Vol | OI | IV |
|---|---|---|---|---|---|---|
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
Puts
| Strike | Last | Bid | Ask | Vol | OI | IV |
|---|---|---|---|---|---|---|
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
Every listed expiry, both sides of the book, with volume, open interest and implied volatility.
Risk profile
Beta vs SPY
—
—
Correlation to SPY
—
—
Realised vol 30D
—
Annualised
Market vol 1Y
—
SPY, annualised
Max drawdown 1Y
—
Peak to trough
Max drawdown 5Y
—
Peak to trough
ATR 14
—
Average true range
Beta (reported)
—
5Y monthly, from filing
Headlines
TechnologyMatch and Get IT Sense Partner to Create a Better Technology Buying Experience
PR Newswire · 4m ago
Confluence Financial Partners Announces Strategic Partnership with Constellation Wealth Capital
PR Newswire · 5m ago
MEDIA ADVISORY - Parliamentary Secretary Casey to announce investment in workforce training to support the life sciences and biomanufacturing sector
CNW Group · 5m ago
Georgia Forestry Foundation Partners with Huber Engineered Woods to Name Les Bateson the 2026 Georgia Forestry Teacher of the Year
PR Newswire · 6m ago
FNCL vs. FTXO: Which Financial Sector ETF Is the Better Buy for Investors?
Motley Fool · 8m ago
CORRECTION – Algosoup Named an OpenAI Select Partner
GlobeNewswire · 9m ago
Equifax agrees to $100 million settlement over credit score errors: What happens next
Yahoo Personal Finance · 10m ago
Nvidia's Longest Losing Streak Since 2022 Is Dragging on the Nasdaq
Barrons.com · 10m ago
PRIVATE STRATEGY · BY QUALIFICATION
The same data. A different seat.
The research you are reading is the input layer for a discretionary options program we run for a small number of qualified investors. Minimum $1,000,000.